Creative BioMolecules Announces New Data Supporting Development of an OP-1-based Therapy for Parkinson's Disease.HOPKINTON, Mass.--(BW HealthWire)--Oct. 26, 1999-- Creative BioMolecules This page aims to list articles on Wikipedia that describe particular biomolecules or types of biomolecules. This list is not necessarily complete or up to date - if you see an article that should be here but isn't (or one that shouldn't be here but is), please update the page , Inc. (Nasdaq: CBMI CBMI Christian Blind Mission International (Australia) CBMI Content Based Multimedia Indexing CBMI Commercial Building Mold Inspector ) announced today new data in support of the Company's development of a therapy to treat Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . The data, presented at the Annual Meeting of the Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. , indicates that OP-1 restores dopaminergic neurons in an animal model of Parkinson's disease. Dopamine dopamine (dōp`əmēn), one of the intermediate substances in the biosynthesis of epinephrine and norepinephrine. See catecholamine. dopamine One of the catecholamines, widely distributed in the central nervous system. is a key chemical in the brain which enables coordinated motor movement. Restoring the function of dopaminergic neurons may provide a new therapeutic avenue in the treatment of Parkinson's disease. Creative BioMolecules has an active program in the development of morphogenic protein-based therapies for injury and disease of the central nervous system. Its lead neurological product opportunity in stroke recovery is expected to moved toward clinical investigation with an Investigational New Drug application planned in the third quarter of 2000. The Parkinson's disease research described in this presentation confirms the affect of OP-1 in the central nervous system and provides a longer term product opportunity. "Factors that promote the survival or prevent the progressive deterioration of dopaminergic neurons may have significant benefit in treating Parkinson's disease. This preclinical study indicates that OP-1 can restore dopamine levels in an animal model of the disease," commented Paula C. Bickford, PhD, Associate Professor of Pharmacology at the University of Colorado University of Colorado may refer to:
In the study, animals were administered OP-1 or a vehicle one week after injury in a rat model of Parkinson's disease. Upon evaluation at week five, animals treated with OP-1 showed a significant increase in dopamine levels in comparison to the vehicle-treated group. A corresponding increase in the enzyme tyrosine hydroxylase Tyrosine hydroxylase or tyrosine 3-monooxygenase is the enzyme responsible for catalyzing the conversion of the amino acid L-tyrosine to dihydroxyphenylalanine (DOPA). , needed for dopamine synthesis, was observed in the substantia nigra substantia ni·gra n. A layer of large pigmented nerve cells in the mesencephalon that produce dopamine and whose destruction is associated with Parkinson's disease. Also called nigra. of treated rats. The study suggests that OP-1 may promote survival of neurons in the substantia nigra--a region of the brain implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in Parkinson's disease. The study was conducted by researchers at the University of Colorado and Creative BioMolecules and supported by a Phase I Small Business Innovation Research grant from the National Institutes of Health. Annually, in the United States there are approximately 50,000 newly diagnosed cases of Parkinson's disease adding to the estimated 1,000,000 existing victims. Parkinson's disease has a significant impact on the quality of life of those afflicted af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, . Symptoms include stiffness, tremors, slowness of movement, difficulty with balance, and difficulty in walking. Creative BioMolecules is a biopharmaceutical company developing therapies for human tissue repair and regeneration. The company is focused on morphogenic protein-based therapies to enhance stroke recovery and treat renal disease Renal disease Kidney disease. Mentioned in: Glycogen Storage Diseases hypertension High blood pressure Cardiovascular disease An abnormal ↑ systemic arterial pressure, corresponding to a systolic BP of > 160 mm Hg . Both applications are currently undergoing preclinical development, with the submission of INDs to begin clinical trials expected in 2000. The first product resulting from Creative BioMolecules' technology, the OP-1 Implant(TM) for orthopaedic reconstruction, is licensed to Stryker Corporation and is under regulatory review for approval in the U.S. and Europe. This news release includes forward-looking statements that involve risks and uncertainties. Factors which could cause actual results to differ from the Company's expectations include, without limitation, preclinical demonstration of safety and efficacy in the neurology field, the course of its preclinical and clinical development programs, including the achievement of development milestones by the Company and/or its partners, the initiation, progress and successful completion of human clinical testing, the timely receipt of regulatory approval required for clinical testing, manufacturing and marketing of products, the impact of competitive products, and the other risks and uncertainties detailed from time to time in the Company's periodic reports. NOTE: For additional information, please consult Creative BioMolecules' homepage at http://www.creativebio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion